Internationale Partnersuche
Innovation & Technologie Angebot
A Russian company with technology for analysing the human genome seeks partners to conclude research cooperation agreement
Country of Origin: Russia
Reference Number: TORU20210428001
Publication Date: 28 April 2021
Summary
A Russian company is engaged in sequencing on modern platforms and primary processing of biodata to order. The company is looking for partners to conclude research cooperation agreement. The company is focused on scientific cooperation. The company is also focused on participation in R&D.
Description
The Russian company from Moscow region was founded in 2014. The company possesses technology for analysis of the human genome using high-throughput sequencing methods of 2 and 3 generations: NGS (Next generation sequencing) и TGS (Third generation sequencing.
Research centres and biobanks work with the laboratory as a reference laboratory since it guarantees the timing and quality of data processing.
All research results are stored on a secure server, and the company ensures their confidentiality.
The company provides services such as:
- panel sequencing (Highly efficient sequencing of gene panels to identify mutations that lead to the manifestation of specific hereditary diseases).
- full-exome sequencing (Highly efficient sequencing of clinically significant regions of the human genome (clinical exome) to identify mutations that lead to the manifestation of hereditary diseases).
- NGS and TGS sequencing (Conducting work for scientific projects using Illumina high-performance NGS platforms and third-generation sequencing on the Oxford Nanopore platform. A full range of services for the preparation and analysis of all types of DNA and RNA libraries. Analysis of RNA and DNA of viruses).
- genotyping (Investigation of point mutations in genes by real-time PCR. A simple and effective method for analysing a small number of the most important genes).
- Functional gene sequencing (16S 18S).
- PCR tests for COVID-19.
There is no experience in implementing international projects, but the company is interested in participating.
There is no certification, but the company is interested in obtaining it.
The company is looking for international partners such as companies, active in the pharmaceutical field, universities, and research centres. The types of partnership considered are research agreement, to explore the innovative application and research and development solution on genetic research.
Advantages and Innovations
Thanks to an extensive network of research centers and biobanks, the company was able to significantly reduce analysis time and improve the accuracy of results.
The company conducts R & D in the following areas:
1) Prototype of a technology for determining the strain identity of the SARS-CoV-2 virus by full-genome RNA genome sequencing using third-generation sequencing technology (TGS);
2) Commercialization of a unique technology for testing coronavirus infection using NGS.
Stage Of Development
Already on the market
Requested partner
The company has successfully worked with Wageningen University & Research and plans to continue working with foreign universities or companies, active in the pharmaceutical field. There is also interest in working with research institutes, and also planing to participate in R&D.
The types of partnership considered are research agreement, to explore the innovative application and research and development solution on genetic research.
Kooperationsanfrage stellen